Rheumatoid Arthritis in Practice An Expert Commentary With Roy Fleischmann, MD A Clinical Context Report. Jointly Sponsored by: and. Rheumatoid Arthritis in Practice. Rheumatoid Arthritis in Practice Expert Commentary.
Rheumatoid Arthritis in Practice
Rheumatoid Arthritis in PracticeExpert Commentary
Supported in part by educational grants from Abbott and Centocor Ortho Biotech.
The goal of this series is to provide up-to-date information and multiple perspectives on the pathogenesis, symptoms, risk factors, and complications of rheumatoid arthritis as well as current and emerging treatments and best practices in the management of rheumatoid arthritis.
Rheumatologists, pain management specialists, geriatricians, family practice/primary care physicians, nurses, nurse practitioners, physician assistants, pharmacists. and other healthcare professionals involved in the management of patients with rheumatoid arthritis.
Upon successful completion of this educational program, participants should be able to:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Pennsylvania School of Medicine and MedPage Today. The University of Pennsylvania School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Pennsylvania School of Medicine Office of CME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MedPage Today "News-Based CME" has been reviewed and is acceptable for up to 2098 Elective credits by the American Academy of Family Physicians. AAFP accreditation begins January 1, 2011. Term of approval is for one year from this date. Each article is approved for 0.5 Elective credits. Credit may be claimed for one year from the date of each article.
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service.
Roy Fleischmann, MD
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Roy Fleischmann, MD,
has disclosed that he has no relevant financial relationships or conflicts of interest to report.
Dori F. Zaleznik, MD, Associate Clinical Professor of Medicine, Harvard Medical School, Boston; Nancy Walsh; and Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner;have disclosed that they have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational activity.
The staff of The University of Pennsylvania School of Medicine Office of CME, MedPage Today, and Projects In Knowledge have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational activity.
Reference: Felson D, et al “American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials”Arthritis Rheum 2011; 63: 573-586.
Biologic Drugs for RA-2 (cont’d)
The Patient’s Choice
Responses at week 24
Source: Taylor P, et al “Ofatumumab, a fully human anti-CD20 MAB in the treatment of biologic-naïve rheumatoid arthritis patients: a randomized, double-blind, placebo-controlled clinical trial”EULAR 2011; Abstract OP0019.
Source: Fleischmann R, et al “Phase 3 study of oral JAK inhibitor tasocitinib (CP-690,550) monotherapy in patients with active rheumatoid arthritis”; ACR 2011; Abstract L8.
At the end of this activity, participants should understand: